Also known as SST · Somatotropin release-inhibiting factor · SRIF · GHIH · Octreotide (analog) · Sandostatin
The universal "off switch" — a cyclic hormone that inhibits growth hormone, insulin, glucagon, and gut secretions; its analog octreotide is the workhorse drug.
Research refreshed
Somatostatin is an inhibitory hormone with unusually broad reach: it suppresses the release of growth hormone, insulin, glucagon, gastrin, and a range of other pancreatic and gastrointestinal secretions. The endogenous 14-residue cyclic peptide has a half-life of only a couple of minutes, so the therapeutics that exploit its biology are stabilized analogs — octreotide (Sandostatin) and lanreotide — used for acromegaly and hormone-secreting neuroendocrine tumors.
Somatostatin is the body’s general inhibitory signal in the endocrine system. Discovered as the hypothalamic factor that blocks growth-hormone release (hence "growth-hormone-inhibiting hormone"), it turned out to be far more widely distributed — in pancreatic delta cells, throughout the gut, and in the nervous system — where it brakes the secretion of insulin, glucagon, gastrin, secretin, and more. It is the counterweight to the body’s many "go" signals.
Its therapeutic problem is its virtue: it shuts off so much, so briefly. Native somatostatin is cleared within minutes, which makes the raw hormone impractical as a drug. The solution was engineering — octreotide is a synthetic eight-residue analog that keeps the essential receptor-binding core, resists degradation, and lasts long enough to dose. Long-acting depot formulations of octreotide and lanreotide now stretch that to monthly injections.
Clinically these analogs are the standard medical therapy for acromegaly (growth-hormone excess) and for controlling the hormone-driven symptoms of neuroendocrine tumors such as carcinoid syndrome. The same broad inhibition also makes them useful in certain GI bleeding and secretory states. Somatostatin is the clearest example in this catalog of a hormone too short-lived to use directly, productively reborn as a stabilized analog.
Agonist at five somatostatin receptor subtypes (SSTR1–5), Gi-coupled, lowering cAMP and inhibiting hormone secretion across the pituitary, pancreatic islets, and GI tract. Octreotide is biased toward SSTR2/SSTR5, which carry the clinically useful growth-hormone- and tumor-suppressing effects.
Behind every vial of Somatostatin is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Somatostatin, specifically, is brought into being.
On paper, Somatostatin weighs in at roughly 1,637.9 daltons. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Somatostatin is built one protected residue at a time by solid-phase synthesis, each cycle a deprotection, a coupling, and a wash. It also carries cyclization and a disulfide bridge, extra steps beyond a plain chain that add both capability and cost.
The crude mixture — Somatostatin plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of Somatostatin proves itself: identity confirmed by mass spectrometry against its ~1,637.9 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Somatostatin — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
A cyclic 14-mer requiring regioselective formation of the 3–14 disulfide after chain assembly. The native peptide is rarely the product worth making — its minutes-long half-life makes it impractical — so the synthetic target is octreotide: the 14-mer distilled to a protease-resistant 8-residue cyclic analog incorporating D-Phe and D-Trp and a reduced C-terminal threoninol. Those D-residue couplings and the controlled disulfide cyclization are the hard steps, and they are exactly what stretch the half-life from minutes to hours. A defining case of pharmacophore minimization in peptide drug design.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning Somatostatin, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
A cyclic peptide hormone that broadly inhibits secretion — of growth hormone, insulin, glucagon, and many gut hormones. It acts as a general "off switch" across the endocrine and digestive systems.
Native somatostatin is cleared within minutes, too briefly to be a practical drug. Octreotide is a stabilized synthetic analog that keeps the key receptor-binding region but resists breakdown, so it can be dosed and even formulated as a long-acting depot.
Its analogs are standard therapy for acromegaly and for controlling hormone-related symptoms of neuroendocrine tumors such as carcinoid syndrome. This page is a research and educational reference, not treatment guidance.
No — this is a research and educational reference, not dosing guidance.
The archetypal protein biologic — a 51-amino-acid two-chain hormone, disulfide-linked, and the first recombinant DNA drug ever marketed.
ViewInsulin’s counter-hormone — a 29-amino-acid peptide that raises blood glucose, the emergency rescue for severe lows, and the "G" in the new triple agonists.
ViewThe active fragment of parathyroid hormone — a recombinant peptide that builds bone, exploiting a paradox: the same hormone resorbs bone when continuous, but builds it when pulsed.
ViewDosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.